Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Raw Materials (2016 - 2021)

Guided Therapeutics (GTHP) has disclosed Raw Materials for 8 consecutive years, with $1.3 million as the latest value for Q1 2021.

  • Quarterly Raw Materials rose 63.09% to $1.3 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Mar 2021, up 63.09% year-over-year, with the annual reading at $1.3 million for FY2020, 63.38% up from the prior year.
  • Raw Materials hit $1.3 million in Q1 2021 for Guided Therapeutics, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.3 million in Q1 2021 to a low of $781000.0 in Q1 2019.
  • Historically, Raw Materials has averaged $844294.1 across 5 years, with a median of $789000.0 in 2017.
  • Biggest five-year swings in Raw Materials: fell 7.77% in 2017 and later surged 63.38% in 2020.
  • Year by year, Raw Materials stood at $789000.0 in 2017, then fell by 0.76% to $783000.0 in 2018, then decreased by 0.26% to $781000.0 in 2019, then soared by 63.38% to $1.3 million in 2020, then increased by 0.08% to $1.3 million in 2021.
  • Business Quant data shows Raw Materials for GTHP at $1.3 million in Q1 2021, $1.3 million in Q4 2020, and $782000.0 in Q3 2020.